Early Experience With Teprotumumab for Chronic Thyroid Eye Disease [PDF]
American Journal of Ophthalmology Case Reports, 2020 Purpose: To report the first case of a patient with chronic thyroid eye disease (TED) treated with teprotumumab. Observations: A 50-year-old female with a 3-year history of Graves’ disease presented with bilateral exophthalmos greatest on the left side ...
Daniel J Ozzello, Don O Kikkawa
exaly +4 more sources
Audiology Findings in Patients With Teprotumumab Associated Otologic Symptoms
American Journal of Ophthalmology Case Reports, 2021 Purpose: To report a case series of subjective and objective hearing function changes associated with teprotumumab treatment for thyroid eye disease.
Tatiana Correa +2 more
exaly +3 more sources
A Case of Ulcerative Colitis Associated With Teprotumumab Treatment for Thyroid Eye Disease
American Journal of Ophthalmology Case Reports, 2021 Purpose: To present a case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease. Observations: A 46-year-old Indian female was treated with teprotumumab (Tepezza) for severe thyroid eye disease within 9 months of diagnosis.
Rona Z Silkiss, Myra Safo
exaly +3 more sources
Effects of Teprotumumab on Patients With Long-Standing, Active Thyroid Eye Disease
American Journal of Ophthalmology Case Reports, 2022 Purpose: Describe five cases of long-standing, active thyroid eye disease that responded to treatment with teprotumumab. Observations: Five patients with a greater than 9-month-history of thyroid eye disease, including two patients who had previously ...
Kyle B. Vinson, MD, Maria Kirzhner, MD
exaly +3 more sources
Audiologic Assessment and Management of Teprotumumab-Associated Ototoxicity: An Updated Narrative Review [PDF]
Audiology ResearchIntroduction: Teprotumumab (Tepezza®), an insulin-like growth factor-1 receptor (IGF-1R) antagonist, is the first FDA-approved targeted therapy for thyroid eye disease (TED).
John Williams +4 more
doaj +2 more sources
Extraocular muscle volume reduction in a patient treated with two courses of teprotumumab for thyroid eye disease [PDF]
American Journal of Ophthalmology Case ReportsPurpose: To report magnetic resonance imaging (MRI) extraocular muscle (EOM) volume analysis in a patient with thyroid eye disease (TED) who was treated with two full courses of teprotumumab.
Hanna Richkind +5 more
doaj +2 more sources
The dual IGF-1R/IR blocker, Linsitinib, modulates human orbital fibroblast activity and proliferation [PDF]
Frontiers in ImmunologyAimThe insulin-like growth factor-1 receptor (IGF-1R) and its downstream signaling pathways drive proliferation, survival, and extracellular matrix production, representing key therapeutic targets in thyroid eye disease (TED).
Maximilian Luffy +8 more
doaj +2 more sources
Patients with Thyroid Eye Disease Initiating Teprotumumab: A Real-World Cohort Study Using the Linked IRIS-Komodo Database [PDF]
Clinical OphthalmologyLouise A Mawn,1 Erin Moore Shriver,2 Madhura Tamhankar,3 Yao Yuan,4 Ann Xi,4 Juan Ayala-Haedo,4 Haridarshan Patel41Department of Ophthalmology, Vanderbilt University Medical Center, Vanderbilt Eye Institute, Nashville, TN, USA; 2Department of ...
Mawn LA +6 more
doaj +2 more sources
American Journal of Ophthalmology Case Reports, 2021 Purpose: To report two cases of thyroid eye disease (TED) associated compressive optic neuropathy (CON) that resolved after treatment with teprotumumab.
Edith R Reshef +2 more
exaly +3 more sources
Redefining evidence for teprotumumab in thyroid eye disease: an updated meta-analysis of efficacy and safety [PDF]
Frontiers in EndocrinologyBackgroundThyroid eye disease (TED) is a sight-threatening autoimmune disorder with limited effective therapies. Teprotumumab, an insulin-like growth factor-1 receptor inhibitor, has emerged as a promising treatment. However, a comprehensive synthesis of
Rongjing Song +8 more
doaj +2 more sources